Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer

Thrombosis and Haemostasis

Volumn 101, Issue 4, 2009, Pages 741-747

  Talieri, Maroulio ^a   Mathioudaki, Konstantina ^a   Prezas, Panagiotis ^a   Alexopoulou, Dimitra K ^a   Diamandis, Eleftherios P ^b   Xynopoulos, Dimitris ^a   Ardavanis, Alexandros ^a   Arnogiannaki, Niki ^a   Scorilas, Andreas ^c  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cell lines; Colorectal cancer; Human stratum corneum chymotryptic enzyme; KLK7; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; STRATUM CORNEUM CHYMOTRYPTIC ENZYME;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CELL LINE; COLON ADENOMA; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISEASE MARKER; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRATUM CORNEUM; STRUCTURAL HOMOLOGY; UPREGULATION;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COLITIS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; KALLIKREINS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 62549113142     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-07-0471     Document Type: Article

References (48)

1. American Cancer Society. Cancer facts and figures, 2005. Atlanta: American Cancer Society 2005.
2. McCracken M, et al. Cancer incidence, mortality, and associated risk factors among asian americans of chinese, filipino, vietnamese, korean, and Japanese ethnicities. CA Cancer J Clin 2007; 57: 190-205.
3. Duffy MJ, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003; 39: 718-727.
4. Anwar S, et al. Systematic review of genetic influences on the prognosis of colorectal cancer. Brit J Surg 2004; 91: 1275-1291.
5. Borgono CA, Diamandis E P. The emerging roles of human kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-890.
6. Yousef GM, Diamandis E P. Tissue kallikrein: new players in normal and abnormal cell growth. Thromb Haemost 2003; 90: 7-16.
7. Hansson L, et al. Cloning, expression and characterization of stratum corneum chymotryptic enzyme. J Biol Chem 1994; 269: 19420-19426.
8. Yousef GM, et al. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family; genomic characterization, mapping, tissue expression, and hormonal regulation. Gene 2000; 254: 119-128.
9. Ekholm IE, et al. Stratum corneum tryptic enzyme in normal edidermis: a missing link in the desquamation process. J Invest Dermatol 2000; 114: 56-63.
10. Descargues P, et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrom. J Invest Dermatol 2006; 126: 1622-1632.
11. Caubet C, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 2004; 122: 1235-1244.
12. Brattsand M, et al. A proteolytic cascade of kallikreins in the stratum corneum J Invest Dermatol 2005; 124: 198-203.
13. Talieri M, et al. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost 2004; 91: 180-186.
14. Dong Y, et al. Differential splicing of KLK5 and KLK7 in epithelial Ovarian Cancer produces Novel variants with potential as cancer biomarkers. Clin Cancer Res 2003; 9: 1710-1720.
15. Shan SJ, et al. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin Chem 2006; 52:1879-1886.
16. Holzscheiter L, et al. Quantititative reverse transcription-PCR assay for detection of mRNA encoding full- length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression levels in breast cancer. Clin Chem 20006; 52: 1070-1079.
17. Santin AD, et al. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecol Oncol 2004; 94: 283-288.
18. Singh J, et al. Expression of kallikrein-related peptidases (KRP/Hk5, 7 6, 8) in subtypes of human lung carcinoma. International Immunopharmacology 2008; 8, 300-306.
19. Planque Ch, et al. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res 2008; 14: 1355-1362.
20. Prezas P, et al. Human tissue Kallikreins 7 and 8 gene expression in intracranial tumors: a clinical study in Greece. Biol Chem 2006; 387: 613-618.
21. Rittenhouse HG, et al. Human Kallikrein 2 (hK2) and prostatic specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci1998; 35: 275-268.
22. Yousef GM, et al. In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. Anticancer Res 2004; 24: 43-51.
23. Ogawa K, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res 2005; 11: 2889-2893.
24. Feng B, et al. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol 206; 21: 1596-1603.
25. Mathioudaki K, et al. Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biol Chem 2004; 385: 779-783
26. Mathioudaki K, et al. SR-A1 gene , member of the human pre-mRNA splicing factors and its expression in colon cancer progression. Biol Chem 2004; 385: 785-790.
27. Talieri M, et al. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb Haemost 2003; 89: 1081-1088.
28. Leoutsakou Th, et al. Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. Biochem Biophys Res Commun 2006; 344: 667-674.
29. Leoutsakou T, et al. Prognostic significance of the expression of SR-A1, encoding a novel SR- related CTD-associated factor, in breast cancer. Biol Chem 2006; 387: 1613-1618.
30. Talieri M, et al. Cathepsin B and Cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett 2004; 205: 97-106.
31. Dorn J, et al. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. Clin Cancer Res 2007; 13: 1742-1748.
32. Petraki CD, et al. Cellular distribution of human tissue kallikreins: immunohistochemical localization. Biol Chem 2006; 387: 653-663.
33. Emami N, Diamandis E P. Human tissue kallikreins: A road under construction Clin Chim Acta 2007; 381: 78-84.
34. Kountourakis P, et al. Expression and prognostic significance of human kallikrein 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thromb Haemost 2009; 101: 541-546.
35. Thomadaki H, et al. Treatment of PC3 prostate cancer cells with Mitoxanthrone, Etoposide, Doxorubicin and Carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemost 2009; 101: 373-380.
36. Papachristopoulou G, et al. Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost 2009; 101: 381-387.
37. Chung CH, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004; 5: 489-500.
38. Roman-Gomez J, et al. The normal epithelial cellspecific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 2004; 18: 362-365.
39. Christophi G P, et al. Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J. Neurochem 2004; 91: 1439-1449.
40. Pampalakis G, et al. The epigenetic basis for the aberrant expression of kallikreins in human cancers. Biol Chem 2006; 387: 795-799.
41. Pampalakis G, et al. Cloning and chracterization of novel isoforms of the human kallikrein 6 gene. Biochem Biophys Res Commun 2004; 320: 54-61.
42. Shaw J, Diamandis E P. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-1432.
43. Johnson SK, et al. Kallikrein 7 enhances pancreatic cancer cell invation by shedding E-cadherin. Cancer 2007; 109: 1811-1820.
44. Dong Y, et al. Tissue-specific promoter utilisation of the kallikrein-related peptidase genes, KLK5 and KLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function. Biol Chem 2008; 389: 99-109.
45. Ramani VC, Haun RS. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem Biophys Res Commun 2008; 369: 1169-1173.
46. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 2007; 1776: 22-31.
47. Paliouras M, Diamandis E P. The kallikrein world: an update on the human tissue kallikreins. Biol Chem 2006; 387: 643-652.
48. Lundwall A, Brattsand M. Kallikrein-related peptidases. Cell Mol Life Sci 2008; 65: 2019-2038.